Search form

 

Press Releases


Axcan to Present at the UBS Global Specialty Pharmaceuticals Conference in New York City


May 21, 2004 - 12:00 ET

Axcan to Present at the UBS Global Specialty Pharmaceuticals Conference in New York City

MONT SAINT-HILAIRE, Quebec, May 21 - Axcan Pharma Inc.
("Axcan" or the "Company") today announced that on Tuesday, May 25, 2004,
David W. Mims, Executive Vice-President and Chief Operating Officer of the
Company, will present an overview of the Company's strategy and growth drivers
at the UBS 2004 Global Speciality Pharmaceuticals Conference held in New York
City. This presentation will take place at 2:00 P.M. EDT.

Interested parties can access the audio webcast of the presentation on
the Company's website at www.axcan.com .

Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology. The Company markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.
Axcan's products are marketed by its own sales force in North America and
Europe. Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".


    "Safe Harbor" statement under the Private Securities Litigation Reform
    ----------------------------------------------------------------------
    Act of 1995.
    ------------
    To the extent any statements made in this release contain information
    that is not historical, these statements are essentially forward looking
    and are subject to risks and uncertainties, including the difficulty of
    predicting FDA and other regulatory approvals, acceptance and demand for
    new pharmaceutical products, the impact of competitive products and
    pricing, new product development and launch, reliance on key strategic
    alliances, availability of raw materials, the regulatory environment,
    fluctuations in operating results and other risks detailed from time to
    time in the Company's filings with the Securities and Exchange Commission
    and the Canadian Multijurisdictional Disclosure System.


David W. Mims
Executive Vice President and 
Chief Operating Officer
Axcan Pharma Inc.
(205) 991-8085 ext. 223 or
Julie M. Thibodeau
Manager, Investor Relations
Axcan Pharma Inc.
(450) 467-2600 ext. 2062
www.axcan.com